02190nas a2200433   4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653001000111653003100121653003000152653001100182653001100193653002300204653001200227653000900239653001600248653001200264653003000276653001500306653002200321653003000343100001100373700001200384700001200396700001400408700001500422700001300437700001200450245016900462300001000631490000700641050001500648520107900663022001401742       2008                            d  c2008 May10aAdolescent10aAdult10aAged10aAged, 80 and over10aChild10aDrug Resistance, Microbial10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aMyanmar10apolymerase chain reaction10aRecurrence10aTreatment Outcome10aWorld Health Organization1 aKyaw K1 aTsoh TM1 aSwe SYY1 aNagaoka Y1 aTakezaki S1 aSuzuki K1 aIshii N00aClinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.  a264-90 v35  aKYAW 2008A3 a<p>This study included 200 randomly selected multibacillary leprosy cases who had completed 1 year of fixed World Health Organization recommended multidrug therapy (WHO-MDT) without prior dapsone (DDS) monotherapy. The time interval after release from treatment varied from a few months to 8 years. All cases were clinically reviewed in 2006 by comparison with their old clinical records. Reactions, particularly reversal reactions, occurred frequently among patients who had completed MDT within the last 3 years. It was difficult to distinguish relapse cases and late reversal reactions in skin smear-negative multibacillary cases. Based on bacteriological and histological analyses, one patient was confirmed to have relapsed 1 year after release from treatment. The overall relapse rate was 0.5%. No drug resistance mutations were detected by polymerase chain reaction or dot blot hybridization. The present study indicates that it is important to follow up patients for several years after completion of MDT in order to detect possible lepra reactions and relapses.</p>  a0385-2407